Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07054684 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of BHV-1400 in IgA Nephropathy

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 1 of 15 sitesv11
  2. Trial sites expanded: 12 → 15 locationsv10
  3. Study sites: 11 to 12v9
  4. Enrollment target: 10 to 20
    • Primary and study completion dates: Jul 2026 to Jul 2027
    v8
  5. Study sites: 10 to 11v7
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 8 to 10v6
  2. Study sites: 7 to 8v5
  3. Study sites: 6 to 7v4
  4. Study sites: 5 to 6v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 5
    • Start date changed from estimate of Jul 2025 to Jul 30, 2025
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
Trial Details
NCT Number NCT07054684
Lead Sponsor Biohaven Therapeutics Ltd.
Conditions
(from sponsor)		 IgA Nephropathy
Related terms Glomerulonephritis, Glomerulonephritis, IGA, Kidney Diseases, Nephritis, Proteinuria, Renal Insufficiency, Chronic, Urologic Diseases
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov